Page 23 - ARTFILLER PROFESSIONAL BROCHURE

EINE SICHERE UND BEWÄHRTE

KOLLEKTION VON FILLERN

IN-VITRO- UND KLINISCHE STUDIEN

GUTES SICHERHEITS- UND VERTRÄGLICHKEITSPROFIL (5)

ADVERSE EVENT AT D0 AFTER INJECTION
Die Anzahl der Fälle von Nebenwirkungen
ist geringer als bei der Marktreferenz.
®
Außerdem sind bei ART FILLER VOLUME
die inflammatorischen Reaktionen
deutlich geringer im Vergleich zur
Marktreferenz.

(EXPRESSION VON ENTZÜNDUNGSMARKERN IN DER
KUTANEN EX-VIVO MIKRODIALYSE)

STUDIEN UND VERÖFFENTLICHUNGEN

GOX.0000000000003274. PMID: 33425589; PMCID: skin aging parameters. Fanian F, Philippon V, Gorj
PMC7787280. M, Rumyantseva Mathey E,Caillens M, Goorochurn R,
Curic S, Humbert P. Clin Cosmet Investig Dermatol.
Comparative clinical study for the efficacy and safety 2023;16:1095-1105 https://doi.org/10.2147/CCID.
Prospective, split-face, randomized, long-term of two different hyaluronic acid-based fillers with S372490.
®
blinded objective comparison of the performance TRI-HYAL versus Vycross technology: a long-term
and tolerability of two new hyaluronic acid fillers. prospective randomized clinical trial. Braccini F, Long-term efficacy and safety of a hyaluronic acid
®
Trevidic P, Andre P, Benadiba L, Deutsch JJ, Galatoire Fanian F, Garcia P, Delmar H, Loreto F, Benadiba dermal filler based on TRI-HYAL Technology on
O, Garcia P, Grand-Vincent A, Boisnic S, Kerihuel JC, L, Nadra K, Kestemont P. J Cosmet Dermatol. 2023 restoration of midface volume. Kestemont P, Fanian
Salomon C. Dermatol Surg. 2017 Dec;43(12):1448- Feb;22(2):473-485. doi: 10.1111/jocd.15200. Epub F, Garcia P, Grand-Vincent A, Benadiba L, Delmar H,
1457. doi: 10.1097/DSS.0000000000001193. Erratum 2022 Jul 19. PMID: 35770300; PMCID: PMC10084174. Bodokh I, Brun P, Braccini F, Desouches C, Paris J,
in: Dermatol Surg. 2018 Aug;44(8):1158. PMID: Nadra K, Salomon C, Trevidic P. J Cosmet Dermatol.
28595250. A prospective multicenter clinical trial evaluating 2023 Sep;22(9):2448-2456. doi: 10.1111/jocd.15752.
the efficacy and safety of a hyaluronic acid-based Epub 2023 May 2. PMID: 37128822.
®
Triple cross-linked hyaluronic acid based on filler with TRI-HYAL Technology in the treatment of
TRI-HYAL technique has more durable effect on lips and the peri-oral area. Ehlinger-David A, Gorj M,
®
dermal renewal. Chen R, Yang W, Sun J, Liu Y, An Braccini F, Loreto F, Grand-Vincent A, Garcia P, Taieb SCANNEN, UM ALLE
Q, Zhang F, Bai Z, Luan Q. Clin Cosmet Investig M, Benadiba L, Catoni I, Mathey ER, Deutsch JJ, VERÖFFENTLICHUNGEN ZU
Dermatol. 2022;15:691-701 https://doi.org/10.2147/ Bahadoran P, Vincent T, David M, Cartier H, Nadra SEHEN
CCID.S362785. K, Moellhoff N, Fanian F.. J Cosmet Dermatol. 2023
Feb;22(2):464-472. doi: 10.1111/jocd.15169. Epub
A hyaluronic acid-based filler reduces lipolysis in 2022 Jul 31. PMID: 35718985; PMCID: PMC10087550.
human mature adipocytes and maintains adherence
and lipid accumulation of long-term differentiated Long-term efficacy and tolerability of a medium
®
human preadipocytes. Nadra K, André M, Marchaud g’ ha filler with TRI-HYAL Technology on the
E, Kestemont P, Braccini F, Cartier H, Kéophiphath M, rejuvenation of the mobile facial zone. David M,
Fanian F. J Cosmet Dermatol. 2021 May;20(5):1474- Braccini F, Garcia P, Loreto F, Benadiba L, Gorj M,
1482. doi: 10.1111/jocd.13794. Epub 2020 Nov 4. Grand-Vincent A, Rumyantseva Mathey E, Deutsch
PMID: 33150734; PMCID: PMC8246837. JJ, Ehlinger A, Cartier H, Nadra K, Fanian F. Clin
Cosmet Investig Dermatol. 2023 Jul 13;16:1795-
Objective 18-month comparison of the tolerability 1805. doi: 10.2147/CCID.S395353. PMID: 37465030;
of 2 dermal fillers formulated with TRI-HYAL PMCID: PMC10351526.
®
Technology. Trevidic P, Andre P, Benadiba L,
Deutsch JJ, Galatoire O, Garcia P, Grand-Vincent A, Evaluation of the performance and tolerance
Boisnic S, Salomon C, Fanian F. Plast Reconstr Surg of the combination of an HA-based filler with
®
Glob Open. 2020 Dec 9;8(12):e3274. doi: 10.1097/ TRI-HYAL Technology and a skin biorevitalizer on